Naropin 0.1% cum sufentanil — Competitive Intelligence Brief

Naropin 0.1% cum sufentanil (Naropin 0.1% cum sufentanil) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic with opioid analgesic combination. Area: Anesthesia, Pain Management.

phase 3 Local anesthetic with opioid analgesic combination Voltage-gated sodium channels (ropivacaine); mu-opioid receptor (sufentanil) Anesthesia, Pain Management Small molecule

Target snapshot

Naropin 0.1% cum sufentanil (Naropin 0.1% cum sufentanil) — Bent Gymoese Jorgensen. Naropin (ropivacaine) is a local anesthetic that blocks sodium channels in nerve membranes, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naropin 0.1% cum sufentanil TARGET	Naropin 0.1% cum sufentanil	Bent Gymoese Jorgensen	phase 3	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu-opioid receptor (sufentanil)
Levobupivacaine and Fentanyl	Levobupivacaine and Fentanyl	Hamad Medical Corporation	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels; mu-opioid receptor
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Ropivacaine/Fentanyl	Ropivacaine/Fentanyl	National Institute for Tuberculosis and Lung Diseases, Poland	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu opioid receptor (fentanyl)
Bupivacaine and Fentanyl	Bupivacaine and Fentanyl	Bnai Zion Medical Center	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (fentanyl)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic with opioid analgesic combination class)

1. Bent Gymoese Jorgensen · 1 drug in this class
2. Bnai Zion Medical Center · 1 drug in this class
3. Conrad Arnfinn Bjørshol · 1 drug in this class
4. Hamad Medical Corporation · 1 drug in this class
5. National Institute for Tuberculosis and Lung Diseases, Poland · 1 drug in this class